← Leaderboards
Laurel McGrane
Fimbrion Therapeutics, Inc.
$750,000
Attributed
$1,500,000
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $600K · FY2023–25$1M$750K$500K$250K$0
'23
'24
'25
Funding mix
By agency
NIH$1,500,000 · 3
By mechanism
R43$1,500,000 · 3
Top collaborators
- Michael Einer Hibbing3 shared
- Thomas Joseph Hannan2 shared
Most similar at Fimbrion Therapeutics, Inc.
Same institution · by research overlap
- Thomas Joseph Hannan$6,586,896
- Michael Einer Hibbing$450,000
- Zachary Cusumano$300,000
- Nicholas Jentsch$150,000
Others in their field
Other Rising Stars on “Oral”
- Supriya Menezes · The Emmes Company, Llc$25,277,032
- Suma Babu · Massachusetts General Hospital$15,344,018
- Sabrina Paganoni · Massachusetts General Hospital$15,344,018
- Heinz Ernst Moser · University Of Texas Med Br Galveston$13,657,841
- Eric Anderson · Columbia University Health Sciences$11,474,975
- Benjamin M Greenberg · Ut Southwestern Medical Center$11,474,975
Research focus
OralMouse ModelNovel TherapeuticsInnovationLead OptimizationMissionIn VitroCellsCommercial ApplicationInfectionIn VivoLeadAntimicrobial ResistanceLibrariesDrug KineticsDrug DesignBacteriaAnti-Bacterial AgentsAntibiotic ResistanceCombatAntibioticsHalf-LifeBiological AvailabilityPharmaceutical Preparations
Grant awards (5)
Small Molecule Glycoside Inhibitors of LecB for the Treatment of Pseudomonas Infections$300,000
R43 · FY2025 · AI
FimH-Targeting Antibody-Recruiting Molecules as Novel Drugs for Preventing Complicated Urinary Tract Infections$300,000
R43 · FY2024 · AI · contact PI
Thiazolino-Pyridone Compounds as Novel Drugs for Tuberculosis$300,000
R43 · FY2024 · AI
FimH-Targeting Antibody-Recruiting Molecules as Novel Drugs for Preventing Complicated Urinary Tract Infections$300,000
R43 · FY2023 · AI · contact PI
Thiazolino-Pyridone Compounds as Novel Drugs for Tuberculosis$300,000
R43 · FY2023 · AI